Associations - CD137 agonist

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	PRS-343 Sensitive: C2 – Inclusion Criteria PRS-343 Sensitive : C2	PRS-343 Sensitive: C2 – Inclusion Criteria PRS-343 Sensitive : C2
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	PRS-343 Sensitive: C2 – Inclusion Criteria PRS-343 Sensitive : C2	PRS-343 Sensitive: C2 – Inclusion Criteria PRS-343 Sensitive : C2
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	PRS-343 Sensitive: C2 – Inclusion Criteria PRS-343 Sensitive : C2	PRS-343 Sensitive: C2 – Inclusion Criteria PRS-343 Sensitive : C2
HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	PRS-343 Sensitive: C3 – Early Trials PRS-343 Sensitive : C3	PRS-343 Sensitive: C3 – Early Trials PRS-343 Sensitive : C3
HER-2 positive	Biliary Tract Cancer	HER-2 positive	Biliary Tract Cancer	PRS-343 Sensitive: C3 – Early Trials PRS-343 Sensitive : C3	PRS-343 Sensitive: C3 – Early Trials PRS-343 Sensitive : C3
HER-2 positive	Urothelial Cancer	HER-2 positive	Urothelial Cancer	PRS-343 Sensitive: C3 – Early Trials PRS-343 Sensitive : C3	PRS-343 Sensitive: C3 – Early Trials PRS-343 Sensitive : C3
CD20 positive	Non-Hodgkin’s Lymphoma	CD20 positive	Non-Hodgkin’s Lymphoma	rituximab + PF-05082566 Sensitive: C3 – Early Trials rituximab + PF-05082566 Sensitive : C3	rituximab + PF-05082566 Sensitive: C3 – Early Trials rituximab + PF-05082566 Sensitive : C3
CLDN18.2 expression	Gastroesophageal Cancer	CLDN18.2 expression	Gastroesophageal Cancer	TJ-CD4B Sensitive: C3 – Early Trials TJ-CD4B Sensitive : C3	TJ-CD4B Sensitive: C3 – Early Trials TJ-CD4B Sensitive : C3
HER-2 positive	Pancreatic Cancer	HER-2 positive	Pancreatic Cancer	PRS-343 Sensitive: C4 – Case Studies PRS-343 Sensitive : C4	PRS-343 Sensitive: C4 – Case Studies PRS-343 Sensitive : C4
HER-2 positive	Melanoma	HER-2 positive	Melanoma	PRS-343 Sensitive: C4 – Case Studies PRS-343 Sensitive : C4	PRS-343 Sensitive: C4 – Case Studies PRS-343 Sensitive : C4
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	PM1003 Sensitive: C4 – Case Studies PM1003 Sensitive : C4	PM1003 Sensitive: C4 – Case Studies PM1003 Sensitive : C4
HER-2 expression	Solid Tumor	HER-2 expression	Solid Tumor	ABL105 Sensitive: D – Preclinical ABL105 Sensitive : D	ABL105 Sensitive: D – Preclinical ABL105 Sensitive : D
TPBG expression	Solid Tumor	TPBG expression	Solid Tumor	ALG.APV-527 Sensitive: D – Preclinical ALG.APV-527 Sensitive : D	ALG.APV-527 Sensitive: D – Preclinical ALG.APV-527 Sensitive : D
CLDN18.2 expression	Solid Tumor	CLDN18.2 expression	Solid Tumor	TJ-CD4B Sensitive: D – Preclinical TJ-CD4B Sensitive : D	TJ-CD4B Sensitive: D – Preclinical TJ-CD4B Sensitive : D
PD-L1 expression	Colon Cancer	PD-L1 expression	Colon Cancer	Opal Sensitive: D – Preclinical Opal Sensitive : D	Opal Sensitive: D – Preclinical Opal Sensitive : D
ROR1 positive	Lung Cancer	ROR1 positive	Lung Cancer	GNC-035 Sensitive: D – Preclinical GNC-035 Sensitive : D	GNC-035 Sensitive: D – Preclinical GNC-035 Sensitive : D
MELTF expression	Solid Tumor	MELTF expression	Solid Tumor	PF-08046049 Sensitive: D – Preclinical PF-08046049 Sensitive : D	PF-08046049 Sensitive: D – Preclinical PF-08046049 Sensitive : D
MSLN overexpression	Solid Tumor	MSLN overexpression	Solid Tumor	HK013 Sensitive: D – Preclinical HK013 Sensitive : D	HK013 Sensitive: D – Preclinical HK013 Sensitive : D
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	TJ-CD4B Sensitive: D – Preclinical TJ-CD4B Sensitive : D	TJ-CD4B Sensitive: D – Preclinical TJ-CD4B Sensitive : D
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	nivolumab + TJ-CD4B Sensitive: D – Preclinical nivolumab + TJ-CD4B Sensitive : D	nivolumab + TJ-CD4B Sensitive: D – Preclinical nivolumab + TJ-CD4B Sensitive : D

Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.

CD137 agonist

CD137 agonist

Associations(20)

Associations
(20)